Core Viewpoint - Zhonghui Biotech-B (02627) has seen a stock increase of over 7%, currently at 46.5 HKD with a trading volume of 18.84 million HKD, following a recommendation from health experts for annual flu vaccinations for all individuals over 6 months old without contraindications [1] Group 1: Product and Market Performance - Huiliankangxin is the first and only quadrivalent subunit flu vaccine in China, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions compared to split vaccines [1] - The product was approved for domestic market launch in 2023, targeting individuals aged 3 and above, with plans to expand to those over 6 months old by 2025 [1] - Projected revenue for 2024 is 260 million RMB, representing a year-on-year growth of 398% [1] Group 2: Company Development and Strategy - The company has developed a comprehensive vaccine development support platform and proprietary technology platform, aligning with international trends through years of research [1] - The company is advancing both innovative vaccine research and traditional vaccine upgrades, creating a rich pipeline of vaccines [1] - In addition to the quadrivalent flu vaccine and human diploid cell rabies vaccine, the company is actively developing 11 other vaccines to address unmet public health needs and market gaps [1]
港股异动 | 中慧生物-B(02627)涨超7% 国内流感疫苗潜在增长空间广阔